德国拜耳的拜瑞妥可治疗什么病症？

Xarelto () is produced by Bayer Healthcare GmbH, a company headquartered in Leverkusen, Germany. It has 750 production plants in 200 locations on six continents; it has 120,000 employees and 350 branches in almost all countries around the world. Polymers, medicine and health care, chemical industry and agriculture are the company's four pillar industries. What conditions does Bayer's Xarelto treat?

The approved indications for Bayer's Xareltorivaroxaban in Germany include: 1. For the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. 2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

Xarelto for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery: The recommended dose is 10 mg orally once daily. If the wound has stopped bleeding, the first medication should be taken between 6 and 10 hours after surgery. For patients who have undergone major hip surgery, the recommended treatment course is 35 days. For patients who have undergone major knee surgery, the recommended treatment course is 12 days. If a missed dose occurs, the patient should take rivaroxaban immediately and continue to take the drug once a day the next day.

Xarelto is used in adult patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism: the recommended dose is 20 mg once a day, which is also the maximum recommended dose. For patients with low body weight and advanced age (>75 years old), doctors can use 15 mg once a day as appropriate based on the patient's condition. In situations where the benefits of preventing stroke and systemic embolism outweigh the risks of bleeding, long-term treatment should be considered.

Recommended related hot articles: /newsDetail/92103.html